Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tablet-based Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced NSCLC or Advanced Pancreatic Cancer With Focus on Cancer Cachexia

NCT02983500 is registered in ClinicalTrials.gov with iOMEDICO AG as lead sponsor.

NCT NCT02983500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02983500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tablet-based Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced NSCLC or Advanced Pancreatic Cancer With Focus on Cancer Cachexia
Lead sponsor
iOMEDICO AG
Phase
Observational
Overall status
Completed
Start date
August 28, 2016
Completion date
July 24, 2019
Enrollment
253 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer, nsclc, metastatic